Hormone-resistant prostate, breast cancers added to clinical trial of experimental DNA therapy

By | August 3, 2021
The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology’s Elenagen, an experimental DNA therapy, to include two new arms: 1) hormone-resistant breast cancer; and 2) hormone-resistant metastatic prostate cancer.